Evidence map›Paper›PMID 36974548›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2023

Discrimination between Precancerous Gastric Lesions and Gastritis Using a Gastric Cancer Risk Stratification Model.

John D Murphy, Meira Epplein, Feng-Chang Lin, Melissa A Troester, Hazel B Nichols, Julia Butt, Kaifeng Pan, Weicheng You, Andrew Olshan

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

John D MurphyUniversity of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Epidemiology, Chapel Hill, NC, USA.ORCID 0000-0002-7714-9976
Meira EppleinDuke University, Department of Population Health Sciences, and Duke Cancer Institute, Cancer Risk, Detection, and Interception Program, Durham, NC, USA.
Feng-Chang LinUniversity of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Biostatistics, Chapel Hill, NC, USA.
Melissa A TroesterUniversity of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Epidemiology, Chapel Hill, NC, USA.
Hazel B NicholsUniversity of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Epidemiology, Chapel Hill, NC, USA.
Julia ButtDeutsches Krebsforschungszentrum, Heidelberg, Germany.
Kaifeng PanPeking University Cancer Hospital, Beijing, China.
Weicheng YouPeking University Cancer Hospital, Beijing, China.
Andrew OlshanUniversity of North Carolina at Chapel Hill, Gillings School of Global Public Health, Department of Epidemiology, Chapel Hill, NC, USA.
University of North Carolina at Chapel Hill · USPeking University · CNDuke University · USGerman Cancer Research Center · DE

Funding

UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
Helicobacter pylori blood biomarker for gastric cancer risk in East AsiaR01CA174853 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI EPPLEIN, MEIRA · 2013 to 2016
$2.3M
NCI NIH HHS R01 CA174853NCI NIH HHS T32 CA057726NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

backgroundSeropositivity to certain Helicobacter pylori proteins may affect development of gastric lesions that could become cancerous. Previously, we developed a model of gastric cancer risk including gender, age, HP0305 sero-positivity, HP1564 sero-positivity, UreA antibody titer and serologically defined chronic atrophic gastritis (termed: "Lasso model").

methodsWe evaluated the Lasso model's ability to discriminate individuals with precancerous gastric lesions (n=320) from individuals with superficial or mild atrophic gastritis (n=226) in Linqu County, China, a population at high risk for gastric cancer. We also compared its performance to the ABC Method, a gastric cancer risk stratification tool currently used in East Asia.

resultsFor distinguishing precancerous lesions from those with gastritis, the receiver operating characteristic curve had an area under the curve (AUC) of 73.41% (95% CI: 69.10%, 77.71%) and, at Youden's Index, a sensitivity of 78.44% (59.38%, 82.50%) and specificity of 64.72% (95% CI: 58.85%, 81.42%). Positive predictive value (PPV) was 75.38% (72.78%, 82.51%). Specificity, AUC and PPV were significantly greater (p < 0.05) than those of the ABC Method. When specificity was held constant, the Lasso model had greater sensitivity, PPV and negative predictive value (NPV) than the ABC Method. However, adjusting the ABC Method for age and gender negated the Lasso model's significant improvement in AUC.

conclusionsThe Lasso model for gastric cancer risk prediction can classify precancerous lesions with significantly greater AUC than the ABC Method and, at constant specificity, with greater sensitivity, PPV and NPV. However, adding age and gender to the ABC Method, as included in the Lasso model, substantially improved its performance and negated the Lasso model's advantage.

Indexed as

GastritisGastritis, AtrophicHelicobacter InfectionsHelicobacter pyloriPrecancerous ConditionsStomach NeoplasmsHumansRisk AssessmentBiostatisticsEpidemiologyMachine Learningprecancerous lesionsrisk stratification

Identifiers

PMID36974548
PMCPMC10334080
OpenAlexW4361206183

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.